ArticleEye (London, England)2025
Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to: 'Comment on: 'Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database".Eye (London, England) · 2026Article
- Comment on: 'Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database'.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucous membrane pemphigoid with ocular involvement (oMMP) is an autoimmune disease that results in chronic conjunctivitis, conjunctival scarring, and if left untreated, permanent vision loss. oMMP is quite rare with incidence rates between one in 12,000 to one in 60,000, but there is a lack of large population-based studies that focus solely on oMMP. Thus, we sought to examine the cumulative and annual incidence and prevalence of oMMP in the TriNetX database and compared these findings to the US population for greater generalizability.
methodsThis was a retrospective study utilised International Classification of Disease, 10th edition (ICD-10) codes to determine the yearly and cumulative incidence and prevalence, demographics, ocular complications, and immunosuppressant treatments prescribed for oMMP from 2013 to 2023. TriNetX software was used to analyze the data.
resultsA total of 4052 patients were diagnosed with oMMP with a mean age of 73 years (SD = 14; range 18-90). The majority of patients were female (n = 2604 64.26%) and non-Hispanic, white (n = 3098, 76.46%). Prednisone was the most common systemic medication prescribed to 40% of patients. The most used immunosuppressive drug was mycophenolate mofetil (21%). Glaucoma was the most common ocular complication (n = 375, 9.25%). Between 2013 and 2023, there was a continuous rise in the cumulative incidence and prevalence rates. The 11-year cumulative incidence and prevalence were 1.41per 100,000 persons and 6.72 per 100,000 persons, respectively.
conclusionsCompared to current literature, the TriNetX population with oMMP had similar demographics and immunosuppressant use, but showed a higher incidence and an overall increasing prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.